Chronic lymphocytic leukaemia in the cat: 18 cases (2000-2010)
Chronic lymphocytic leukaemia in the cat: 18 cases (2000-2010)
复制标题
DOI：
10.1111/j.1476-5829.2011.00315.x
复制
发表时间：
2013-12-01
影响因子：
2.1
通讯作者：
Williams, L. E.
中科院分区：
文献类型：
--
作者：
Campbell, M. W.;Hess, P. R.;Williams, L. E.
关于慢性淋巴细胞白血病（CLL）猫的表现、生物学行为、治疗和预后的信息很少，需要进一步研究以表征猫的这种疾病。本研究的目的是描述猫CLL的临床表现、治疗反应和预后。对2000年至2010年期间诊断为CLL的18只猫进行了多机构回顾性研究。CLL定义为存在成熟淋巴细胞增多（>= 9000淋巴细胞μ L-1），并确认免疫表型单态性或克隆性淋巴样群体。每个患者还需要具有以下两个标准中的至少一个：（1）至少一种细胞系的并发血细胞减少和/或（2）骨髓中>15%的成熟淋巴细胞。本文回顾了其临床表现、病史、临床体征、临床病理特征和治疗反应。初次就诊时猫的中位年龄为12.5岁（范围：5-20岁）。最常见的主诉是慢性体重减轻，8/18（44%）只猫出现。18只猫中有16只（89%）接受苯丁酸氮芥和泼尼松龙给药;其中4只猫还接受长春新碱给药。2只（11%）猫接受了多药注射化疗（L-CHOP、L-天冬酰胺酶、环磷酰胺、多柔比星、长春新碱、泼尼松龙）。88%的可评价反应的猫实现了完全（9只猫）或部分（6只猫）缓解。中位总体缓解时间为15.7个月（范围：1.3-22.8个月）。有随访数据的17只猫的中位总生存期为14.4个月（范围：0.9-25.3个月）。这项研究的结果表明，慢性淋巴细胞白血病影响老年猫，并积极响应与口服苯丁酸氮芥和泼尼松龙治疗。
There is little information regarding the presentation, biologic behaviour, treatment and prognosis in cats with chronic lymphocytic leukaemia (CLL), and further investigation is needed to characterize this disease in cats. The goal of this study was to describe the clinical presentation, response to treatment and prognosis of feline CLL. A multi-institutional retrospective study of 18 cats diagnosed with CLL between 2000 and 2010 was performed. CLL was defined as the presence of a mature lymphocytosis (>= 9000 lymphocytes mu L-1) and confirmation of an immunophenotypically monomorphic or clonal lymphoid population. Each patient was required to also have at least one of the two following criteria: (1) concurrent cytopenia of at least one cell line and/or (2) >15% mature lymphocytes in the bone marrow. Data on signalment, history, clinical signs, clinicopathologic features and response to treatment were reviewed. Median age of the cats at initial presentation was 12.5 years (range: 5-20 years). The most common presenting complaint was chronic weight loss, which was present in 8/18 (44%) cats. Sixteen of 18 (89%) cats were treated with chlorambucil and prednisolone; four of these cats also received vincristine. Two (11%) cats were treated with multi-agent injectable chemotherapy (L-CHOP, L-asparaginase, cyclophosphamide, doxorubicin, vincristine, prednisolone). Eighty-eight percent of cats evaluable for response achieved a complete (nine cats) or partial (six cats) remission. Median overall remission was 15.7 months (range: 1.3-22.8 months). The median overall survival in the 17 cats with follow-up data was 14.4 months (range: 0.9-25.3 months). Results of this study suggest that CLL affects older-aged cats and responds favourably to treatment with oral chlorambucil and prednisolone.